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Abstract
Background Prurigo is defined by the presence of chronic pruritus and multiple localized or generalized pruriginous
lesions.
Objective The aim of this study was to assess the psychological burden of prurigo in patients of European countries.
Methods In this multicentre European study, 3635 general dermatology outpatients and 1359 controls were included.
Socio-demographic data and answers to questionnaires (regarding quality of life, general health, anxiety and depression
and suicidal ideation) were collected.
Results There were 27 patients with prurigo; of these, 63% were men, and the mean age was 58.6 years. Among
patients with prurigo, 10 of 27 (37%) suffered from anxiety and 8 of 27 (29%) from depression. Suicidal ideation was
reported in 5 of 27 (19%) patients, and for four of these five patients, suicidal ideation was related to their skin disease.
These frequencies were higher in the 10 commonest dermatological diseases (including psoriasis, atopic dermatitis and
leg ulcers). The impact on quality of life was severe, with a mean Dermatologic Life Quality Index (DLQI) of 12.4, with an
extreme impact on quality of life for 23% of patients and a very large impact for 27% of patients.
Conclusion The psychological comorbidities of prurigo are common, greater than those of other skin diseases, and
their impact on quality of life is significant. Thus, it is important to study this condition and to find new treatments.
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Prurigo occurs along with chronic pruritus and presents with
symmetrically distributed papules, nodules and/or plaques.1 This
disorder is characterized by intense pruritus as the dominant
symptom.2,3 The skin between the lesions is usually normal. The
term prurigo, or prurigo nodularis, has been used for many dec-
ades without a clear definition. Recently, the European experts
of the Task Force Pruritus of the European Academy of Derma-
tology and Venereology achieved a consensus regarding the defi-
nition, classification and terminology of prurigo.4 The major
criteria are chronic pruritus (≥6 weeks), history and/or signs of
repeated scratching (e.g. excoriations and scars) and localized or
generalized presence of multiple pruriginous lesions. These
lesions occur due to a neuronal sensitization to itch and the
development of an itch–scratch cycle.4 Prurigo is related to a
neuronal sensitization to itch and development of an itch–
scratch cycle. Prurigo can be associated with pruritus of derma-
tological, systemic, neurologic, psychiatric/psychosomatic, mul-
tifactorial or undetermined origin. It is still a matter of
controversy whether prurigo represents a separate entity or is a
reaction pattern due to the vicious circle of repeated itching and
scratching. The treatment of prurigo remains challenging
because data from randomized controlled trials are sparse.5–8
Some molecules are in development, such as neurokinin-1
receptor antagonists or antagonists for IL-31.9 Little is known
about the prevalence of comorbidities associated with prurigo,
particularly psychiatric disorders, such as anxiety and depres-
sion. The aim of this study was to select available data about
prurigo out of a larger dataset from the large multicentre Euro-
pean study of general dermatology outpatients and to assess the
psychological burden of the condition in these patients.
Patients and methods
Participants
A multicentre observational cross-sectional study had been con-
ducted in 13 European countries.10 Consecutive dermatology
outpatients were invited to participate on random days. The
inclusion criteria were age >18 years, understanding the local
language and not suffering from severe psychosis. A control
group of healthy workers was invited to participate. Data were
available for 3635 patients and 1359 controls. Each patient was
clinically examined by the dermatologist, who recorded the diag-
nosis, its severity and comorbidities, including cardiovascular
disease, chronic respiratory disease, diabetes mellitus, rheumato-
logical disease and other diseases such as cancer. The 10 more
common dermatological diseases of the entire study were psoria-
sis, non-melanoma skin cancer, skin infections, eczema, acne,
nevi, atopic eczema, benign skin tumours, hand eczema and leg
ulcers. In this study, we identified cases of prurigo and com-
pared their data to control patients and patients with other der-
matological diseases.
Questionnaires
Each participant was asked to complete a two-part document.
The first part contained questions about socio-demographic
variables: sex, age, ethnicity, marital status, education and self-
reported socio-economic status; the second part contained the
following questionnaires:
• The Dermatologic Life Quality Index (DLQI),11 consisting
of ten questions about symptoms, embarrassment, shopping
and home care, clothes, social and leisure, sport, work or
study, close relationships, sex and treatment. Each question
is scored from 0 to 3, giving a possible score range from 0
(no impact of skin disease on quality of life) to 30 (maxi-
mum impact on quality of life). Categories are as follows:
0–1, no effect at all on patient’s life; 2–5, small effect on
patient’s life; 6–10, moderate effect on patient’s life; 11–20,
very large effect on patient’s life; 21–30, extremely large
effect on patient’s life.
• The EuroQol 5-dimensions 3-levels (EQ-5D-3L), consisting
of two parts namely the EQ-5D-3L descriptive system and
the EQ visual analogue scale (EQ VAS).12 The EQ-5D-3L
descriptive system comprises the following five dimensions:
mobility, self-care, usual activities, pain/discomfort and
anxiety/depression. Each dimension has three levels: no
problems, some problems and extreme problems. The EQ
VAS records the respondent’s self-rated health on a vertical
visual analogue scale where the endpoints are labelled ‘best
imaginable health state’ and ‘worst imaginable health state’.
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• The Hospital Anxiety and Depression Scale (HADS), a well-
validated instrument with good psychometric properties,
which has been used to assess the symptoms of anxiety dis-
orders and depression in somatic, psychiatric and primary
care patients, as well as in the general population.13 The
HADS includes seven items that assess anxiety and seven for
depression, each with four possible answers. For each
dimension of anxiety and depression, a score from 0 to 7 is
considered normal, from 8 to 10 is considered a borderline
case and from 11 to 21 is considered a case in need of fur-
ther examination or treatment.
These instruments (DLQI, EQ-5D-3L and HADS) were used
in the validated translations relevant to the study countries.
• To assess suicidal ideation, the item ‘Have you ever thought
of committing suicide?’ with possible answers of ‘yes’ or
‘no’ was included. An additional question was given to the
patient group: ‘Have you ever thought of committing sui-
cide because of your skin condition?’ The dermatologist
answered two questions: ‘Do you see depressive signs in the
patient?’ and ‘Do you see anxiety signs in the patient?’ with
the possible answers: ‘yes’ or ‘no’.
Statistical analysis
All data were analysed using Microsoft Office Excel. The quanti-
tative variables were described using the mean and standard
deviation. The means of the two groups (prurigo patients and
controls) were compared with Student’s t-test. The qualitative
variables were described using the frequency and were compared
between the two groups with a chi-squared test or Fisher’s exact
test in the case of small sample sizes. For all statistical analyses,
the type 1 error was set at 5%. Data of patients with prurigo
were also compared with data of the 10 more frequent skin dis-
eases (psoriasis, non-melanoma skin cancer, skin infections,
eczema, acne, nevi, atopic eczema, benign skin tumours, hand
eczema and leg ulcers) for the HADS score or with all skin dis-
eases for DLQI in a descriptive way.
Results
The details of the participants’ characteristics have been previ-
ously published.10 In this study, we included 27 patients with
prurigo. The socio-demographic characteristics and comorbidities
of patients with prurigo and controls are presented in Table 1.
The severity of prurigo lesions was evaluated by the doctor as
slight in 4 of 20 (20%) patients, mild in 10 of 20 (50%) and sev-
ere in 6 of 20 (30%). Only 14 of 26 (53%) patients claimed to
know their diagnosis. Symptoms were present for more than
1 month in 26 of 27 (96%) cases. To the question, ‘What is your
level of concern about your skin disease?’, 15 of 27 (55%)
patients answered ‘very much’, 10 of 27 (37%) ‘middle’ and 2 of
27 (7%) ‘little’. Patients reported a flare-up of their skin disease
every day in 15 of 26 (57.7%) cases, every week in 3 of 26 (11%),
every month in 3 of 26 (11%) and several times a year in 5 of 26
(19%). Concerning location, 13 of 26 (50%) patients had prur-
igo lesions on the torso, 12 of 26 (46%) on the hands, 7 of 26
(26%) on the scalp and 6 of 26 (23%) on the face. At the time of
examination, 23 of 26 (88%) patients were presented with pruri-
tus. The mean (SD) reported itch intensity was 6.6 (3.1) and
ranged from 0 to 10.
Table 1 Socio-demographic characteristics and comorbidities of








Belgium 2 (7.4) 131 (9.6)
Denmark 3 (11.1) 122 (9.0)
France 1 (3.7) 20 (1.5)
Germany 2 (7.4) 133 (9.8)
Hungary 0 134 (9.9)
Italy 5 (18.5) 46 (3.4)
Netherlands 4 (14.8) 0
Norway 6 (22.2) 218 (16.0)
Poland 2 (7.4) 125 (9.2)
Russia 0 120 (8.8)
Spain 0 116 (8.5)
Turkey 1 (3.7) 109 (8.0)
United Kingdom 1 (3.7) 85 (6.3)
Age, years (MD = 1/18)
Range 28–84 18–89
Mean  SD 58.6  15.1 41.1  13.6 <0.001
Sex, No. (%) (MD = 0/3)
Female 10 (37.0) 903 (66.6) 0.001
Marital status, No. (%) (MD = 5/3)
Single 2 (9.1) 362 (26.7)
Married/partner 15 (68.2) 840 (62.0) 0.017
Separated/divorced 2 (9.1) 119 (8.8)
Widowed 3 (13.6) 34 (2.5)
Educational level, No. (%) (MD = 0/8)
Low 8 (29.6) 375 (27.8)
Higher 18 (66.7) 399 (29.5) <0.001
University 1 (3.7) 577 (42.7)
Stressful events during
last 6 months, No. (%)
(MD = 0/13)
10 (37.0) 412 (30.6) 0.47
Symptoms of depression/anxiety as assessed by the dermatologist,
No. (%)
Depression (MD = 4/7) 5 (21.7) 182 (13.5) 0.22
Anxiety (MD = 4/9) 6 (26.1) 356 (26.4) 0.98
Comorbidities, No. (%)
Heart disease (MD = 2/303) 5 (20.0) 78 (7.4) 0.037
Respiratory (MD = 5/307) 3 (13.1) 47 (4.5) 0.078
Diabetes (MD = 2/305) 4 (16.0) 24 (2.3) 0.003
Rheumatological disease
(MD = 3/305)
1 (4.2) 48 (4.6) 1
MD, missing data (patients/controls).
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Data about anxiety, depression and suicidal ideation for
patients with prurigo and controls are presented in Table 2.
Ten of 27 (37.1%) patients with prurigo suffered from anxiety
were diagnosed with a HADS anxiety score≥ 11, which was sig-
nificantly higher (P < 0.001) not only than that of the controls,
but also for the 10 more common dermatological conditions of
the cohort of patients; in fact, 22.7% (139/612) of patients with
psoriasis, 21.0% (29/138) of patients with hand eczema, 17.6%
(28/159) of patients with atopic eczema, 17.5% (20/114) of
patients with leg ulcers suffered from anxiety.
Similarly, 8 of 27 (29.6%) patients with prurigo suffered from
depression were diagnosed with a HADS depression score ≥11,
which was significantly greater (P < 0.001) than that of the con-
trols (4.3%) and of the 10 other more common dermatological
conditions of the cohort of patients: 24.3% (28/115) of patients
with leg ulcers, 15.1% (21/139) of patients with hand eczema,
13.8% (84/608) of patients with psoriasis and 10.1% (16/158) of
patients with atopic eczema suffered from depression.
Finally, 5 of 27 (19.2%) patients with prurigo reported past or
present suicidal ideation, which was significantly higher
(P = 0.03) than that of controls (8.3%) and of the 10 more com-
mon dermatological conditions of the cohort; in fact, 17.8%
(21/118) of patients with leg ulcers, 17.3% (106/613) of patients
with psoriasis, 15.0% (25/167) of patients with atopic eczema
and 14.2% (20/141) of patients with hand eczema reported suici-
dal ideation. The data about anxiety, depression and suicidal
ideation for the other dermatological conditions are presented
in a previously published study.10
We analysed the concordance of the diagnosis of anxiety and
depression between the dermatologist and that suggested by the
HADS questionnaire in the 27 patients with prurigo. The HADS
questionnaire suggested that there was no depression in 16
patients and the dermatologist in 12 of these 16 patients (75%).
The HADS questionnaire concluded that there was no anxiety in
14 patients and the dermatologist in 11 of these 14 patients
(78%). The true-positive value (represented by the percentage of
dermatologists recognizing signs of depression or anxiety in
depressed or anxious patients defined by HADS ≥11) was 50%
for anxiety and 20% for depression, and the false-negative value
was 66% for depression and 64% for anxiety. The dermatologists
underestimated depression and anxiety in 6 of 23 patients
(26%), respectively. On the other hand, dermatologists overesti-
mated depression in 4 of 23 patients (17%) and anxiety in 3 of
23 patients (13%).
The mean DLQI was 12.4  8.6, with a range from 0 to 30.
The distribution of the score categories of DLQI is presented in
Fig. 1. Compared to the 25 other skin diseases, prurigo had a
large impact on quality of life, the same as hidradenitis suppura-
tiva (DLQI = 12.4  7.3) and greater than that of atopic der-
matitis (11.4  7.1) and pruritus (11.2  7.3). The values for
all the other skin diseases were under 10.
The results of the EQ-5D-3L descriptive system are presented
in Fig. 2. The EQ VAS was 57.4  16.5. Among the dermatolog-
ical diseases studied, prurigo had the third worst self-reported











Mean  SD 8.3  4.8 4.7  3.5
≥ 11 (anxiety clinical case) 10 (37.1%) 150 (11.1%) <0.001
HADS depression
Range 1–16 0–16
Mean  SD 7.6  4.1 4.3  3.2
≥ 11 (depression clinical case) 8 (29.6%) 58 (4.3%) <0.001
Suicidal ideation (MD=1)
Suicidal ideation 5 (19.2%) 88 (8.3%) 0.03
Suicidal ideation concerning
the skin disease (among those
with suicidal ideation)
4 (80.0%) N.A
Suicidal ideation concerning the
skin disease (in the whole sample)
4 (15.4%) N.A


























Figure 1 Dermatologic Life Quality Index (DLQI) score categories













































Figure 2 Results of the 5 dimensions of the EQ-5D-3L descriptive
system for patients with prurigo.
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health, with a score of 57.4, behind leg ulcers (56.0  20.2) and
hidradenitis suppurativa (56.9  20.7).
Discussion
Studies on the psychological consequences of prurigo are scarce.
In our study, anxiety, depression and suicidal ideation were
more common in patients with prurigo than in patients with the
10 other more common dermatological diseases (psoriasis, non-
melanoma skin cancer, skin infections, eczema, acne, nevi, ato-
pic eczema, benign skin tumours, hand eczema and leg ulcers).
A psychometric study from Dazzi et al.14 compared 20
patients with prurigo nodularis to 20 voluntary subjects. Specific
questionnaires were used as follows: the General Health Ques-
tionnaire, State-Trait Anxiety Inventory – form Y, Beck Depres-
sion Inventory II and Eysenck Personality Questionnaire.
Symptoms of trait anxiety and depression were significantly
more common in the group of patients with prurigo than in the
control group (51.3% vs. 39.5% and 19.2% vs. 7.0%, respec-
tively), but there was no significant difference for state anxiety.
A recent epidemiological study based on an analysis of a register
included 877 patients with prurigo nodularis and 8770 con-
trols.15 The frequencies of anxiety and depression and consump-
tion of anxiolytics and antidepressants were significantly higher
in patients with prurigo compared to controls, and there was no
association between prurigo and committed suicide. Depression
was found in 8.5% of patients with prurigo, and anxiety was
only found in 2.1%. This result could be explained in several
ways: the diagnosis was probably not always registered in the
database, and there was probably an underdiagnosis. Another
study compared the psychological comorbidities of 94 patients
with prurigo not to controls but to 91 patients with psoriasis.16
There was no significant difference with regard to alexithymia,
somatization symptoms, hypochondrias, anxiety (present in
18% of patients with prurigo vs. 11% with psoriasis) and depres-
sion (present in 22% of patients with prurigo and 21% of
patients with psoriasis). Psychological comorbidities can be con-
sidered to be a consequence of prurigo, but depression and anxi-
ety can induce pruritus and thereby lead to prurigo.17
Concerning the agreement between dermatologist and HADS,
the true-positive rate was lower in patients with prurigo com-
pared to the entire cohort of patients analysed in a previous
study for depression (20% vs. 44%, respectively) but higher for
anxiety (50% vs. 35%, respectively).18
In a previously published study on the same cohort of
patients, our patients with prurigo had one of the three lowest
mean EQ VAS scores (57.4).19 This value was similar to that of
rheumatoid arthritis pain (56.4) and 25.7 points lower than for
healthy controls.20 Impairment for each of the five dimensions
of the EQ5D for patients with prurigo compared to controls
highlighted an increased odds ratio (between 8.6 and 3.3) for all
dimensions (in descending order): pain/discomfort, self-care,
depression/anxiety, mobility and activity. Among the 35
dermatological diseases studied, for self-care, prurigo was the
worst after blistering disease, and for pain/discomfort, prurigo
was the worst after hidradenitis suppurativa.21
Among all of the dermatological diseases studied, prurigo had
the worst impact on quality of life, with a mean DLQI at 12.4,
the same as hidradenitis suppurativa. Impairment of quality of
life was severe: for half of the patients, it was considered as very
or extremely large. Also, the burden caused by dermatological
therapy was high in patients with prurigo: it was reported in
60.7% of patients, the second worst after atopic dermatitis
(63.4%) in the entire study21. In a previous study including 30
patients with prurigo nodularis treated with pimecrolimus, the
mean DLQI was 11.5.22
The prevalence of prurigo in our study is 0.74%. No study is
available concerning the prevalence of this rare disease. Jor-
gensen identified 877 cases of prurigo in all Danish patients with
a hospital (in- or outpatient) diagnosis of prurigo nodularis
before 2011, but the denominator is unknown.
Men were somewhat more numerous (59.3%) than women
in our group of patients. Prurigo is usually considered to be
more common in women. In a cohort of 108 patients with
prurigo nodularis, females represented 63.9% of the sample.23
Epidemiological data are lacking, so it is difficult to draw con-
clusions concerning the difference between sexes.5 The mean
age of patients in our study was 57, and prurigo usually
appears in middle age (40–60 years old). The mean age was
61.5 years in Iking’s study23. Patients with prurigo reported a
significantly lower level of education than controls (60.9% vs.
27.8%). Some comorbidities, such as heart disease and diabetes,
were significantly more common in patients with prurigo than
in controls. These comorbidities or the drugs used to treat
them could be a cause of prurigo. There is little information
on comorbidities but diabetes was present in 7.4% of patients
in Iking’s cohort.23
This study has some limitations. The sample size is limited,
but prurigo is a rare disease. Previous prospective studies
included 20–108 patients.14,23 Moreover, prurigo was only
defined very recently, so there is probably a heterogeneity of dis-
eases named prurigo in our study, because there was no consen-
sual definition at the time of the study.4 However, the diagnosis
was made by a dermatologist.
Prurigo remains relatively unexplored, but researchers are
increasingly interested in this disease. In particular, the Euro-
pean experts of the Task Force Pruritus published an expert con-
sensus on the definition, classification and terminology of
chronic prurigo.4 The treatment of prurigo remains challenging
but some molecules are in development.5–8
In conclusion, this study highlights prurigo’s significant
impact on quality of life, including the high frequency of
anxiety, depression and suicidal ideation. Thus, this condi-
tion should be further studied to find new approaches to
management.
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